List of Excipients in Branded Drug ADVIL MIGRAINE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Haleon US Holdings LLC	ADVIL MIGRAINE	ibuprofen	0573-0168	D&C YELLOW NO. 10
Haleon US Holdings LLC	ADVIL MIGRAINE	ibuprofen	0573-0168	FD&C GREEN NO. 3
Haleon US Holdings LLC	ADVIL MIGRAINE	ibuprofen	0573-0168	FD&C RED NO. 40

Advil Migraine Excipient Strategy and Commercial Opportunities

Last updated: August 16, 2026

Advil Migraine is an over-the-counter ibuprofen product positioned for migraine-related headache relief. Its commercial differentiation comes primarily from dosage form, liquid-filled softgel delivery, brand recognition, and migraine-specific labeling rather than active-ingredient exclusivity. The core opportunity is to improve ibuprofen solubilization, capsule performance, patient acceptability, stability, and manufacturing economics while remaining within the FDA’s OTC monograph framework.

What is Advil Migraine and which excipients does it use?

Advil Migraine contains ibuprofen, a nonsteroidal anti-inflammatory drug, at 200 mg per liquid-filled capsule. The product is labeled for temporary relief of migraine headache and associated symptoms such as sensitivity to light and sound, subject to the product’s labeling conditions.[1]

The marketed dosage form is a liquid-filled gelatin capsule. Public FDA labeling identifies the inactive ingredients as including:

Excipient or component	Likely formulation role
Gelatin	Softgel shell-forming polymer
Sorbitol	Plasticizer and humectant in the capsule shell
Polyethylene glycol	Solvent or co-solvent in the liquid fill; may also support shell processing
Mineral oil	Processing or shell-related component
Lecithin	Wetting, dispersing, or emulsifying aid
Potassium hydroxide	pH adjustment and ibuprofen solubilization support
Purified water	Processing solvent or shell component
FD&C Blue No. 1	Capsule colorant
Pharmaceutical ink	Printing and product identification

The exact commercial formula, excipient grades, concentrations, manufacturing parameters, and supplier specifications are generally proprietary. FDA labeling provides the ingredient identity but not a complete quantitative composition.[1]

Why is the liquid-filled format commercially important?

Ibuprofen has limited aqueous solubility. A liquid fill can improve drug dispersion and may support faster dissolution than a conventional compressed tablet, depending on the formulation and shell properties. The commercial benefit is a compact dosage form with a smooth mouthfeel and easier swallowing for some consumers.

The liquid-filled softgel also creates manufacturing dependencies. The sponsor must control:

• Ibuprofen particle size and wetting.
• Fill viscosity and capsule weight variation.
• Shell moisture and mechanical strength.
• Gelatin cross-linking risk.
• Leakage and seam integrity.
• Interaction between fill components and shell.
• Long-term dissolution after storage.
• Colorant and printing consistency.

These parameters create know-how barriers even though the active ingredient itself is mature and widely available.

What is the FDA regulatory status of Advil Migraine?

Advil Migraine is an OTC ibuprofen product regulated under the FDA’s OTC monograph framework for internal analgesic, antipyretic, and antirheumatic products. The relevant regulatory framework is codified in 21 C.F.R. Part 343, including the ibuprofen provisions in 21 C.F.R. § 343.110.[2]

The FDA’s OTC monograph system differs from the prescription-drug NDA model. A compliant product can be marketed without an individual NDA if it meets the applicable monograph conditions, including active-ingredient concentration, dosage form, labeling, directions, warnings, and manufacturing requirements.

Regulatory issue	Advil Migraine position
Active ingredient	Ibuprofen
Strength	200 mg per capsule
Category	OTC internal analgesic
Regulatory pathway	OTC monograph framework
Individual NDA reliance	Not generally required for a compliant monograph product
Orange Book listing	Typically not the primary source of product protection for an OTC monograph product
Prescription-drug exclusivity	None identified for the OTC product
Main regulatory constraint	Compliance with the ibuprofen monograph and FDA labeling requirements

FDA’s switch of ibuprofen to OTC status occurred decades ago. The current commercial product therefore does not depend on new chemical-entity exclusivity or active-ingredient patent protection.[3]

What patents protect Advil Migraine?

No commercially meaningful composition-of-matter patent protection remains for ibuprofen. The relevant protection is more likely to reside in proprietary formulation know-how, manufacturing processes, trademarks, packaging, and product-specific regulatory execution.

Composition-of-matter protection

Ibuprofen was discovered and commercialized long before the current U.S. patent term regime. Any original compound patents have expired. Generic manufacturers can produce ibuprofen subject to applicable regulatory and quality requirements.

Formulation patents

Potential formulation patent categories include:

• Liquid-filled ibuprofen formulations.
• Softgel shell compositions.
• Low-water or anhydrous fills.
• Ibuprofen solutions or suspensions.
• Stabilized ibuprofen formulations.
• Rapid-release dosage forms.
• Capsule technologies that reduce leakage or shell brittleness.
• Taste-masked or color-coded products.
• Combination formulations containing ibuprofen and another active ingredient.

These categories may have been the subject of historical patents across the industry, but a patent must be assessed claim by claim, with attention to expiration, terminal disclaimers, maintenance fees, prosecution history, and geographic scope. A generic manufacturer would not normally face a meaningful barrier merely because a patent once covered a liquid softgel concept.

Trademark and trade dress

The Advil and Advil Migraine names are more commercially relevant than expired ibuprofen patents. Trademark rights can restrict branding, packaging appearance, and consumer-facing product presentation, but they do not prevent sale of an equivalent ibuprofen product under a different name.

When does Advil Migraine lose exclusivity?

Advil Migraine has no remaining drug exclusivity comparable to a new prescription product. Its market exclusivity is commercial rather than statutory.

Exclusivity type	Status
New chemical entity exclusivity	Not applicable
Five-year NCE exclusivity	Not applicable
Three-year clinical-investigation exclusivity	Not applicable
Orphan-drug exclusivity	Not applicable
Pediatric exclusivity	Not identified
Active-ingredient patent	Expired
OTC monograph market access	Available to compliant competitors
Trademark protection	Continues subject to use and renewal
Brand loyalty and retail placement	Commercial, not statutory

Competitors can market ibuprofen migraine products if they satisfy the FDA monograph and avoid infringing valid formulation, process, trademark, or packaging rights.

Are there Paragraph IV challenges involving Advil Migraine?

Paragraph IV litigation is generally associated with ANDAs for prescription or NDA-listed products. It is not the normal pathway for a compliant OTC monograph ibuprofen product.

A manufacturer launching an OTC monograph ibuprofen softgel would not ordinarily need to file a Paragraph IV certification against an Advil Migraine Orange Book listing. The relevant risks are different:

• FDA monograph compliance.
• Facility registration and current good manufacturing practice.
• Product quality and stability.
• Labeling compliance.
• Trademark clearance.
• Trade-dress avoidance.
• Patent review for specific softgel or liquid-fill technologies.
• Potential state-law or federal consumer-protection claims.

A Paragraph IV strategy could become relevant if a particular product were marketed under an NDA or if a competitor relied on an approved drug application with listed patents. That is not the principal framework for Advil Migraine.

What excipient strategy can improve Advil Migraine or a competing product?

The strongest opportunities are incremental. They involve performance, cost, sustainability, and patient experience rather than a new therapeutic mechanism.

1. Improve ibuprofen solubilization

Ibuprofen is a weak acid with limited water solubility. Potassium hydroxide can convert part of the drug to a more soluble salt form in the liquid fill. A formulation developer could evaluate:

• Controlled neutralization with potassium hydroxide or another permitted alkalizing agent.
• Polyethylene glycol systems.
• Propylene glycol or glycerol, where compatible with the dosage form and regulatory requirements.
• Surfactant-assisted wetting.
• Lipid-based or self-emulsifying systems.
• Amorphous or micronized ibuprofen.
• Reduced-water formulations to limit hydrolysis and shell interaction.

The formulation must balance solubilization against precipitation after dilution, shell compatibility, viscosity, dose uniformity, and dissolution performance.

2. Reduce gelatin-shell defects

Softgel shells are sensitive to water migration, temperature, humidity, and fill composition. Commercial optimization can focus on:

• Lowering fill components that extract water from gelatin.
• Controlling sorbitol-to-gelatin ratios.
• Selecting gelatin grades with consistent gel strength.
• Evaluating non-gelatin shells such as modified starch, carrageenan, or hypromellose.
• Reducing shell brittleness during storage.
• Improving seam integrity and leak resistance.

A non-gelatin shell could expand the product’s appeal to vegetarian consumers, although it may increase equipment, validation, and stability costs.

3. Replace or reduce petroleum-derived excipients

Mineral oil and some conventional capsule components may create sustainability and consumer-perception concerns. Potential alternatives include:

• Medium-chain triglycerides.
• Vegetable-derived processing aids.
• Bio-based plasticizers.
• Lower-impact colorants.
• Simplified shell systems.
• Recyclable secondary packaging.

Any replacement must preserve capsule mechanics, fill uniformity, dissolution, and shelf life. Sustainability claims would also require substantiation and careful packaging review.

4. Improve swallowability and sensory performance

Migraine patients may experience nausea, vomiting, and light or odor sensitivity. Formulation opportunities include:

• Smaller capsule dimensions.
• Smooth, low-friction shell coatings.
• Reduced odor from fill ingredients.
• Color and imprint designs that support identification without increasing sensory burden.
• Alternative dosage forms such as orally disintegrating tablets, chewable tablets, powders, or liquid sachets.

A rapidly dispersing dosage form may have commercial value, but the sponsor should not claim faster therapeutic relief without adequate comparative clinical or pharmacokinetic evidence.

5. Address excipient tolerability

Ibuprofen products carry gastrointestinal, renal, cardiovascular, and hypersensitivity warnings that are not eliminated by excipient redesign.[1] Excipient selection should avoid adding avoidable tolerability issues, including:

• Excessive polyol levels that may cause gastrointestinal discomfort.
• Colorants that create consumer avoidance or sensitivity concerns.
• Excipients with strong odor or taste.
• Components with allergen or animal-origin implications.
• Shell materials that compromise dose release.

The target is a robust formulation with a narrow excipient system and clear labeling.

What commercial opportunities exist for Advil Migraine competitors?

Private-label and retail-brand softgels

The most immediate opportunity is a store-brand equivalent using 200 mg ibuprofen in a liquid-filled capsule. Because the active ingredient is generic and the OTC monograph is established, the competitive advantage comes from:

• Lower manufacturing cost.
• Retailer-exclusive packaging.
• Multi-count value packs.
• Club-store formats.
• Subscription and e-commerce distribution.
• Combined migraine and general-headache portfolios.

Retailers can compete on price while using a familiar dosage form.

Premium fast-release positioning

A competitor can position a formulation around rapid dissolution, provided the evidence supports the claim. Useful development endpoints include:

• Comparative dissolution under relevant pH conditions.
• Disintegration and rupture time.
• Pharmacokinetic comparison.
• Time to onset in a suitable clinical study.
• Consumer preference and ease-of-swallowing data.

The legal and regulatory risk is claim overreach. "Fast release" and "rapid dissolution" are not interchangeable with "faster pain relief."

Vegetarian and clean-label capsules

A non-gelatin capsule can target consumers avoiding animal-derived ingredients. A simplified excipient declaration can support retail differentiation, but "clean label" is a marketing concept rather than an FDA-recognized therapeutic category.

The principal technical challenge is matching gelatin’s mechanical and sealing performance. Hypromellose and polysaccharide systems may require different drying, sealing, and storage conditions.

Migraine portfolio extensions

A company could develop an OTC migraine line around the same ibuprofen platform:

• Standard 200 mg liquid gels.
• Larger-count value packs.
• Lower-pill-burden formats where permitted.
• Combination products, subject to monograph and labeling requirements.
• Pediatric or age-specific products only where the dosage form and labeling support the intended population.
• Adjunctive products for hydration, nausea, or sensory management, provided claims remain legally distinct from drug claims.

Combination products create a larger opportunity but also increase regulatory complexity, interaction risks, label space, and manufacturing requirements.

Contract manufacturing and licensing

Commercial opportunities exist for companies that own or control:

• Softgel encapsulation capacity.
• High-shear mixing and liquid-fill technology.
• Gelatin or vegetarian-shell platforms.
• Ibuprofen solubilization systems.
• Stability-enhancing packaging.
• Child-resistant and senior-friendly dispensing systems.

The most valuable licensing assets are likely to be process packages and validated manufacturing platforms rather than broad ibuprofen composition patents.

How strong is the patent estate for Advil Migraine?

The estate is weak against generic active-ingredient competition and potentially stronger around narrow implementation details.

Asset category	Relative competitive strength
Ibuprofen molecule	Very low; legacy rights expired
200 mg OTC dosage	Very low
General liquid-filled capsule concept	Low to moderate, depending on claim scope and expiration
Specific excipient ratios	Potentially moderate if claims are narrow and unexpired
Shell and fill compatibility process	Moderate as trade secret or narrow patent
Manufacturing controls	Moderate operational barrier
Brand name and trademarks	High against confusingly similar branding
Retail placement and consumer recognition	High commercial value
Packaging and trade dress	Moderate, subject to non-functionality and distinctiveness

A competitor’s practical barrier is more likely to be scale, quality performance, retail access, and brand investment than patent infringement risk.

What geographic coverage and manufacturing barriers apply?

U.S. OTC monograph compliance does not automatically authorize sales in other markets. Each jurisdiction may impose different requirements for:

• Ibuprofen dose limits.
• Migraine indications.
• Softgel excipients.
• Colorants.
• Gelatin source and bovine or porcine documentation.
• Pharmaceutical-grade raw materials.
• Label warnings.
• Child-resistant packaging.
• Stability zones and shelf-life testing.

Manufacturing barriers include validated softgel equipment, controlled humidity, in-process capsule inspection, fill-weight controls, dissolution testing, and supply reliability for gelatin and specialty excipients. A supplier change can trigger comparability, stability, and regulatory assessment even when the product remains within the same OTC category.

What generic launch risks exist for Advil Migraine?

A generic or private-label launch can proceed without a traditional Paragraph IV event, but it still faces execution risks.

Regulatory and quality risks

• Incorrect OTC labeling.
• Nonconforming active or inactive ingredient use.
• Inadequate stability data.
• Dissolution failure after storage.
• Capsule leakage or brittleness.
• Inconsistent ibuprofen assay.
• Manufacturing deviations.
• Colorant or shell changes that affect appearance and consumer acceptance.

Commercial risks

• Price compression from retailer brands.
• Limited shelf space.
• Dependence on one softgel manufacturer.
• Consumer confusion with established Advil branding.
• Weak differentiation if the product only copies the incumbent dosage form.
• Retailer demands for rapid scale-up and low returns.

IP and legal risks

• Trademark infringement.
• Trade-dress similarity.
• Patent claims covering a specific fill or shell formulation.
• Advertising claims that imply superior onset without evidence.
• Consumer claims tied to migraine-specific performance.

How does Advil Migraine compare with conventional ibuprofen tablets?

Attribute	Advil Migraine liquid softgel	Conventional ibuprofen tablet
Active ingredient	Ibuprofen	Ibuprofen
Typical strength	200 mg	200 mg
Dosage form	Liquid-filled gelatin capsule	Compressed tablet
Excipient complexity	Higher	Generally lower
Manufacturing cost	Usually higher	Usually lower
Swallowing experience	Smooth capsule surface	Tablet texture may be less favorable
Formulation flexibility	High for liquid fills	High for solid dispersions and coatings
Shell-related risks	Leakage, brittleness, cross-linking	Not applicable
Patent differentiation	Usually narrow	Usually narrow
Consumer positioning	Premium or branded	Value and broad availability

The softgel can command a premium when consumers value swallowability, brand trust, or perceived rapid release. Tablets remain structurally advantaged on cost, throughput, packaging efficiency, and supply-chain simplicity.

Key Takeaways

• Advil Migraine is a 200 mg ibuprofen OTC liquid-filled softgel product.
• Its commercial formula includes gelatin, sorbitol, polyethylene glycol, potassium hydroxide, lecithin, mineral oil, colorant, water, and pharmaceutical ink, based on FDA labeling.
• Ibuprofen has no meaningful remaining composition-of-matter exclusivity.
• Paragraph IV litigation is generally not the principal competitive pathway for this OTC monograph product.
• The strongest formulation opportunities involve solubilization, shell integrity, vegetarian capsules, rapid dissolution, reduced excipient burden, and sustainable materials.
• Generic and private-label competition can enter through OTC monograph compliance, subject to trademark, trade dress, quality, and narrow formulation-patent review.
• The principal commercial barriers are manufacturing scale, retail access, validated softgel performance, and brand recognition.
• A defensible new product would likely combine a differentiated dosage form or excipient platform with substantiated performance claims and efficient contract manufacturing.

FAQs

Can a company sell an ibuprofen migraine softgel without an NDA?

A company can generally market a compliant OTC ibuprofen product under the applicable FDA monograph framework without relying on an individual NDA, provided the product meets the monograph, labeling, manufacturing, and other FDA requirements.[2]

Is the gelatin shell of Advil Migraine patent protected?

The general use of a gelatin shell is unlikely to provide meaningful exclusive protection by itself. Patent risk would depend on a specific unexpired claim covering the shell composition, fill composition, manufacturing process, or interaction between those elements.

Can a competitor use the same inactive ingredients as Advil Migraine?

Inactive ingredients may generally be used when permitted for the dosage form and route, and when the finished product complies with FDA requirements. Using the same ingredient list does not authorize copying the Advil name, logo, packaging, or confusingly similar trade dress.

Is a vegetarian Advil Migraine alternative commercially viable?

Yes. A vegetarian softgel could target consumers avoiding animal-derived gelatin. The key development risks are shell strength, sealing, moisture control, dissolution, stability, and manufacturing cost.

Can a competitor claim that its ibuprofen softgel works faster?

Only if the claim is supported by appropriate evidence and is consistent with FDA requirements and advertising law. Comparative dissolution alone may support a release-performance claim but may not establish faster clinical pain relief.

References

1. U.S. Food and Drug Administration. (2023). Advil Migraine liquid-filled capsule, ibuprofen 200 mg: Drug facts labeling. DailyMed. https://dailymed.nlm.nih.gov/

2. Electronic Code of Federal Regulations. (2024). 21 C.F.R. Part 343: Internal analgesic, antipyretic, and antirheumatic drug products for over-the-counter human use. https://www.ecfr.gov/

3. U.S. Food and Drug Administration. (1984). Ibuprofen drug products for over-the-counter human use; final monograph. Federal Register, 49 Fed. Reg. 4574. https://www.federalregister.gov/